CRISPR tech selectively shreds cancer cells, including "undruggable" cancers
Points and comments are a snapshot, not live.
Researchers engineered CRISPR to selectively destroy cancer cells carrying p53 mutations, found in nearly half of all cancers.
Researchers at UC Berkeley, UCSF, and Gladstone Institutes developed a CRISPR-Cas12a2 system that detects mutant RNA transcripts in cancer cells and triggers "chromatin shredding," destroying the cell's genetic material. The approach targets p53 mutations present in nearly half of all cancers and 70-90% of ovarian, pancreatic, and non-small cell lung cancers. In mammalian cell cultures, the system distinguished between healthy and cancerous cells with precision, leaving wild-type cells unharmed despite differing by a single nucleotide. The technique is programmable, allowing researchers to adapt it to new mutations more quickly than developing small molecule drugs. Key limitations include delivery challenges inherent to CRISPR therapies and whether the approach will work in living organisms.
What commenters are saying
Commenters express cautious optimism, framing this as part of a maturing class of tools rather than a single breakthrough. One notes that basic technology progress across many domains is finally crossing adoption thresholds simultaneously. Skepticism centers on delivery challenges and realistic timelines: one commenter estimates a decade for medical inventions to navigate bureaucracy, suggesting this is early-stage despite the Nature publication. Discussion also touches on broader economic allocation, with some questioning why adtech receives more resources than cancer research, though others counter that US pharmaceutical R&D spending ($100 billion annually) already eclipses adtech investment.